Key terms
About BLRX
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BLRX news
Apr 17
11:05am ET
Buy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis Efficiency
Apr 17
8:27am ET
BioLineRx Enhances Multiple Myeloma Treatment
Apr 01
11:27am ET
BiolineRx Ltd. Completes Significant Securities Offering
Apr 01
9:05am ET
BioLineRx to sell 7.5M ADSs at 80c in registered direct offering
Mar 28
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Mar 26
11:45am ET
Buy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst Optimism
Mar 26
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 26, 2024
Mar 26
7:59am ET
BioLineRx Announces Major Commercial Milestones
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 04
7:12am ET
BioLineRx receives Notice of Allowance from USPTO for a patent
Feb 29
6:27am ET
Positive Outlook for Bioline RX with Promising Phase 2 Trial Results and New Product Launch: A Buy Rating
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
7:22am ET
BioLineRx announces dosing of frist patient in CheMo4METPANC Phase 2 trial
No recent press releases are available for BLRX
BLRX Financials
Key terms
Ad Feedback
BLRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BLRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range